2-(dimethylamino)-N-(3-sulfamoyl-phenyl)acetamide | 848051-96-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(dimethylamino)-N-(3-sulfamoyl-phenyl)acetamide
• 英文别名: 2-(dimethylamino)-N-(3-sulfamoylphenyl)acetamide
• CAS: 848051-96-7
• 化学式: C₁₀H₁₅N₃O₃S
• mdl: MFCD07325086
• 分子量: 257.313
• InChiKey: IVKKHYUMYGSDDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-二氯喹喔啉 、 2-(dimethylamino)-N-(3-sulfamoyl-phenyl)acetamide 在 caesium carbonate 作用下， 以 异丁酰胺 为溶剂， 反应 3.0h， 生成 N-(3-(N-(3-chloroquinoxalin-2-yl)sulfamoyl)phenyl)-2-(dimethylamino)acetamide
  参考文献：
  名称：

  [EN] USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER
  [FR] PROCÉDÉS D'UTILISATION DE MODULATEURS PI3K ETMEK

  摘要：

  公开号：

  WO2008021389A8
• 作为产物：
  描述：

  (二甲基氨基)乙酰氯 、 间氨基苯磺酰胺 在 盐酸 、 碳酸氢钠 作用下， 以 水 、 丙酮 为溶剂， 反应 10957.5h， 生成 2-(dimethylamino)-N-(3-sulfamoyl-phenyl)acetamide
  参考文献：
  名称：

  WO2008/127594

  摘要：

  公开号：

文献信息

• Methods of Using PI3K and MEK Modulators
  申请人：Aftab Dana T.

  公开号：US20100075947A1

  公开（公告）日：2010-03-25

  The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.

  本发明提供了一种使用抑制激酶的化合物组合来治疗癌症的方法，更具体地说是抑制MEK和PI3K的化合物组合。
• Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use
  申请人：Bajjalieh William

  公开号：US20100087440A1

  公开（公告）日：2010-04-08

  The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

  本发明涉及磷脂酰肌醇3-激酶（PI3K）的小分子抑制剂，该酶与多种恶性肿瘤相关，如卵巢癌、宫颈癌、乳腺癌、结肠癌、直肠癌和胶质母细胞瘤等。因此，本发明的化合物可用于治疗、预防和/或抑制这些疾病。
• Quinoxaline Compounds and Use Thereof
  申请人：Gaillard Pascale

  公开号：US20100137308A1

  公开（公告）日：2010-06-03

  The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及一种公式（I）的喹啉化合物，特别用于治疗自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。
• Phosphatidylinositol 3-kinase inhibitors and methods of their use
  申请人：Exelixis, Inc.

  公开号：US07989622B2

  公开（公告）日：2011-08-02

  The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

  本发明包括磷脂酰肌醇3-激酶（PI3K）的小分子抑制剂，该酶与多种恶性肿瘤相关，如卵巢癌、宫颈癌、乳腺癌、结肠癌、直肠癌和胶质母细胞瘤等。因此，本发明的化合物可用于治疗、预防和/或抑制这些疾病。
• Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use
  申请人：Bajjalieh William

  公开号：US20110207712A1

  公开（公告）日：2011-08-25

  The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

  本发明涉及磷脂酰肌醇3-激酶（PI3K）的小分子抑制剂，PI3K与多种恶性肿瘤相关，如卵巢癌、宫颈癌、乳腺癌、结肠癌、直肠癌和胶质母细胞瘤等。因此，本发明化合物可用于治疗、预防和/或抑制这些疾病。